

# A Case-based Guide to Diagnosis and Management of Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

## VIRTUAL “ESCAPE RHEUM” RESOURCE GUIDE

### DIAGNOSIS, SUBCLASSIFICATION, GUIDELINES, AND TESTING

[Hemodynamic definitions and clinical classification of PH](#)

[2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension](#)

[Pulmonary function testing to confirm a diagnosis of PH](#)

[Five-year outcomes of patients enrolled in the REVEAL registry](#)

### OPTIMIZING PATIENT TREATMENT

[The importance of patient perspectives in pulmonary hypertension](#)

[Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report](#)

[Collaborative care: a defining characteristic for a pulmonary hypertension center](#)

### CLINICAL TRIALS

[Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension \(CTD-PAH\): subgroup analysis from the AMBITION trial](#)

[Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension \(CTD-PAH\) in the modified intention-to-treat population of the AMBITION study: post hoc analysis](#)

[Macitentan and morbidity and mortality in pulmonary arterial hypertension \(SERAPHIN\)](#)

[Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension \(GRIPHON\)](#)

[Riociguat for the treatment of pulmonary arterial hypertension](#)

[Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2](#)

[Combination therapy with oral treprostinil for pulmonary arterial hypertension \(FREEDOM-EV\)](#)

[Efficacy and safety of initial triple oral versus initial oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension \(TRITON\)](#)